These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 21126631)
21. Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma. Wang M; Weber DM; Delasalle K; Alexanian R Am J Hematol; 2005 Jul; 79(3):194-7. PubMed ID: 15981221 [TBL] [Abstract][Full Text] [Related]
22. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Morgan GJ; Schey SA; Wu P; Srikanth M; Phekoo KJ; Jenner M; Davies FE Br J Haematol; 2007 May; 137(3):268-9. PubMed ID: 17408469 [No Abstract] [Full Text] [Related]
23. [Treatment of multiple myeloma with elotuzumab plus pomalidomide and dexamethasone]. Rasche L; Einsele H; Nitschmann S Internist (Berl); 2019 Jun; 60(6):658-660. PubMed ID: 30941437 [No Abstract] [Full Text] [Related]
24. Lenalidomide plus dexamethasone in multiple myeloma. Das M Lancet Oncol; 2018 Jan; 19(1):e12. PubMed ID: 29175148 [No Abstract] [Full Text] [Related]
25. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide. Richardson P Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100 [TBL] [Abstract][Full Text] [Related]
26. Integrating novel therapies in the transplant paradigm. Harousseau JL Cancer J; 2009; 15(6):479-84. PubMed ID: 20010167 [TBL] [Abstract][Full Text] [Related]
27. Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma. Sidra G; Williams CD; Russell NH; Zaman S; Myers B; Byrne JL Haematologica; 2006 Jun; 91(6):862-3. PubMed ID: 16769594 [TBL] [Abstract][Full Text] [Related]
28. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy. Niesvizky R; Naib T; Christos PJ; Jayabalan D; Furst JR; Jalbrzikowski J; Zafar F; Mark T; Lent R; Pearse RN; Ely S; Leonard JP; Mazumdar M; Chen-Kiang S; Coleman M Br J Haematol; 2007 Sep; 138(5):640-3. PubMed ID: 17686058 [TBL] [Abstract][Full Text] [Related]
29. Thalidomide after lenalidomide: a possible treatment regimen in relapse refractory multiple myeloma patients. Guglielmelli T; Petrucci MT; Saglio G; Palumbo A Br J Haematol; 2011 Jan; 152(1):108-10. PubMed ID: 21083653 [No Abstract] [Full Text] [Related]
31. Combo drug therapy beneficial for new cases of multiple myeloma. Health News; 2006 Feb; 12(2):9. PubMed ID: 16456922 [No Abstract] [Full Text] [Related]
38. CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma. Sanchez E; Li M; Li J; Wang C; Chen H; Jones-Bolin S; Hunter K; Ruggeri B; Berenson JR Leuk Res; 2012 Nov; 36(11):1422-7. PubMed ID: 22906694 [TBL] [Abstract][Full Text] [Related]
39. Role of the TNF-α promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone. Du J; Yuan Z; Zhang C; Fu W; Jiang H; Chen B; Hou J Leuk Res; 2010 Nov; 34(11):1453-8. PubMed ID: 20122728 [TBL] [Abstract][Full Text] [Related]
40. Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study. Offidani M; Corvatta L; Marconi M; Visani G; Alesiani F; Brunori M; Galieni P; Catarini M; Burattini M; Centurioni R; Rupoli S; Scortechini AR; Giuliodori L; Candela M; Capelli D; Montanari M; Olivieri A; Piersantelli MN; Leoni P Haematologica; 2006 Jan; 91(1):133-6. PubMed ID: 16434383 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]